Evaluating the Role of Ruxolitinib as Treatment of Graft-Versus-Host Disease

Tania Jain, MBBS, assistant professor at Johns Hopkins University, discusses the role of ruxolitinib (Jakafi) as treatment of graft-versus-host disease (GVHD). At her institution, she has used ruxolitinib as treatment of GVHD for patients with grade 2 through 4 ...

from Google Alert - Business https://ift.tt/39PpXL3
Tania Jain, MBBS, assistant professor at Johns Hopkins University, discusses the role of ruxolitinib (Jakafi) as treatment of graft-versus-host disease (GVHD). At her institution, she has used ruxolitinib as treatment of GVHD for patients with grade 2 through 4 ... https://ift.tt/eA8V8J

Comments

Popular posts from this blog

Jobless Rate Drops

Electrolytic Fixed Power Capacitors Market Competitive intelligence & regional outlook 2020

USU project among finalists for $3 million solar energy tech prize